Stock Scorer

Ascendis Pharma A/S (ASND)

Ascendis Pharma A/S reported revenue of 247.5M EUR for the quarter ending 31 December 2025, up 42.3% from 173.9M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in EUR. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in EUR.
FigurePeriodAmountYear on year
Revenue Q4 '25 · ending 31 December 2025 247.5M +42.3%
Gross Profit Q4 '25 · ending 31 December 2025 223.9M +40.0%
Operating Income Q4 '25 · ending 31 December 2025 9.9M +2483.6%
Net Income Q4 '25 · ending 31 December 2025 -33.6M —
Cost of Revenue Q4 '25 · ending 31 December 2025 23.6M +68.3%
Operating Cash Flow Q4 '25 · ending 31 December 2025 73.4M —
Free Cash Flow Q3 '24 · ending 30 September 2024 -56.6M —
Shares Outstanding Q3 '25 · ending 30 September 2025 60.8M -0.1%
EPS Q4 '25 · ending 31 December 2025 -3.76 —

Revenue and profit by financial year

As filed, in EUR. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 720.1M-136.3M-228M—
20242024-12-31 363.6M-278.8M-378.1M—
20232023-12-31 266.7M-455.5M-481.4M-469.8M
20222022-12-31 51.2M-561.8M-583.2M-510.2M
20212021-12-31 7.8M-451.8M-383.6M-441.4M
20202020-12-31 7M-330.6M-419M-291.4M
20192019-12-31 13.4M-226.7M-218M-181.1M
20182018-12-31 10.6M-154.8M-130.1M-141.4M
20172017-12-31 1.5M-111.5M-123.9M-96M
20162016-12-31 4.6M-72.9M-68.5M-60.9M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q4 '252025-12-31247.5M
Q3 '252025-09-30213.6M
Q2 '252025-06-30158M
Q1 '252025-03-31101M
Q4 '242024-12-31173.9M
Q3 '242024-09-3057.8M
Q2 '242024-06-3036M
Q1 '242024-03-3195.9M
Q4 '232023-12-31137.7M
Q3 '232023-09-3048M
Q2 '232023-06-3047.4M
Q1 '232023-03-3133.6M
Q4 '222022-12-3122.9M
Q3 '222022-09-3015.3M
Q2 '222022-06-306.2M
Q1 '222022-03-316.8M
Q4 '212021-12-314.9M
Q3 '212021-09-301.1M
Q2 '212021-06-301M
Q1 '212021-03-31746K

Gross Profit Quarterly

PeriodEndingGross Profit
Q4 '252025-12-31223.9M
Q3 '252025-09-30191.3M
Q2 '252025-06-30126.6M
Q1 '252025-03-3183.4M
Q4 '242024-12-31159.9M
Q3 '242024-09-3046.6M
Q2 '242024-06-3024.5M
Q1 '242024-03-3188.3M
Q4 '232023-12-31118.2M
Q3 '232023-09-3040.6M
Q2 '232023-06-3034.5M
Q1 '232023-03-3129M
Q4 '222022-12-3117.8M
Q3 '222022-09-3013.6M
Q2 '222022-06-305.1M
Q1 '222022-03-312.6M
Q4 '212021-12-311.4M
Q3 '212021-09-301.1M
Q2 '212021-06-301M
Q1 '212021-03-31746K

Operating Income Quarterly

PeriodEndingOperating Income
Q4 '252025-12-319.9M
Q3 '252025-09-3011M
Q2 '252025-06-30-53M
Q1 '252025-03-31-104.2M
Q4 '242024-12-31383K
Q3 '242024-09-30-96.7M
Q2 '242024-06-30-133.3M
Q1 '242024-03-31-49.1M
Q4 '232023-12-31-36.6M
Q3 '232023-09-30-134.4M
Q2 '232023-06-30-140.8M
Q1 '232023-03-31-143.7M
Q4 '222022-12-31-147.4M
Q3 '222022-09-30-144.5M
Q2 '222022-06-30-141.9M
Q1 '222022-03-31-128M
Q4 '212021-12-31-112.6M
Q3 '212021-09-30-96.9M
Q2 '212021-06-30-117.6M
Q1 '212021-03-31-124.7M

Net Income Quarterly

PeriodEndingNet Income
Q4 '252025-12-31-33.6M
Q3 '252025-09-30-61M
Q2 '252025-06-30-38.9M
Q1 '252025-03-31-94.6M
Q4 '242024-12-31-38.5M
Q3 '242024-09-30-99.2M
Q2 '242024-06-30-109.4M
Q1 '242024-03-31-131M
Q4 '232023-12-31-86.9M
Q3 '232023-09-30-162.2M
Q2 '232023-06-30-121.4M
Q1 '232023-03-31-110.9M
Q4 '222022-12-31-207.4M
Q3 '222022-09-30-169M
Q2 '222022-06-30-81.3M
Q1 '222022-03-31-125.5M
Q4 '212021-12-31-106.1M
Q3 '212021-09-30-80.3M
Q2 '212021-06-30-134.4M
Q1 '212021-03-31-62.8M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q4 '252025-12-3123.6M
Q3 '252025-09-3022.4M
Q2 '252025-06-3031.4M
Q1 '252025-03-3117.5M
Q4 '242024-12-3114M
Q3 '242024-09-3011.2M
Q2 '242024-06-3011.5M
Q1 '242024-03-317.6M
Q4 '232023-12-3119.5M
Q3 '232023-09-307.4M
Q2 '232023-06-3012.9M
Q1 '232023-03-314.6M
Q4 '222022-12-315.1M
Q3 '222022-09-301.7M
Q2 '222022-06-301.1M
Q1 '222022-03-314.2M
Q4 '212021-12-313.5M
Q3 '212021-09-300
Q2 '212021-06-300
Q1 '212021-03-310

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q4 '252025-12-3173.4M
Q3 '252025-09-302.2M
Q2 '252025-06-30-7.3M
Q1 '252025-03-31-14.3M
Q4 '242024-12-31-87.2M
Q3 '242024-09-30-56.1M
Q2 '242024-06-30-61.3M
Q1 '242024-03-31-101.6M
Q4 '232023-12-31-42.5M
Q3 '232023-09-30-124.7M
Q2 '232023-06-30-153.1M
Q1 '232023-03-31-147M
Q4 '222022-12-31-141.7M
Q3 '222022-09-30-98.8M
Q2 '222022-06-30-124.4M
Q1 '222022-03-31-130.8M
Q4 '212021-12-31-123.3M
Q3 '212021-09-30-97.5M
Q2 '212021-06-30-115.2M
Q1 '212021-03-31-81.6M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q3 '242024-09-30-56.6M
Q2 '242024-06-30-61.6M
Q1 '242024-03-31-101.8M
Q4 '232023-12-31-42.5M
Q3 '232023-09-30-125.7M
Q2 '232023-06-30-153.6M
Q1 '232023-03-31-148.1M
Q4 '222022-12-31-145.5M
Q3 '222022-09-30-102M
Q2 '222022-06-30-128.1M
Q1 '222022-03-31-134.6M
Q4 '212021-12-31-128.1M
Q3 '212021-09-30-108.8M
Q2 '212021-06-30-118.8M
Q1 '212021-03-31-85.6M
Q4 '202020-12-31-94.6M
Q3 '202020-09-30-62.7M
Q2 '202020-06-30-61.2M
Q1 '202020-03-31-72.9M
Q4 '192019-12-31-50.4M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q3 '252025-09-3060.8M
Q2 '252025-06-3063.9M
Q1 '252025-03-3160M
Q3 '242024-09-3057.5M
Q2 '242024-06-3060.8M
Q1 '242024-03-3156.9M
Q3 '232023-09-3056.3M
Q2 '232023-06-3056.2M
Q1 '232023-03-3156.1M
Q3 '222022-09-3055.8M
Q2 '222022-06-3055.8M
Q1 '222022-03-3156.7M
Q3 '212021-09-3054.6M
Q2 '212021-06-3053.8M
Q1 '212021-03-3153.8M
Q3 '202020-09-3052.7M
Q2 '202020-06-3048.2M
Q1 '202020-03-3148M
Q3 '192019-09-3047.6M
Q2 '192019-06-3047.2M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q4 '252025-12-31-3.76
Q3 '252025-09-30-3.82
Q2 '252025-06-30-4.54
Q1 '252025-03-31-5.81
Q4 '242024-12-31-6.53
Q3 '242024-09-30-7.46
Q2 '242024-06-30-8.62
Q1 '242024-03-31-8.87
Q4 '232023-12-31-8.55
Q3 '232023-09-30-10.72
Q2 '232023-06-30-10.87
Q1 '232023-03-31-10.17
Q4 '222022-12-31-10.40